Navigation Links
Ambit Biosciences to Present at Two Upcoming Investor Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Ambit Biosciences today announced that Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib, at two upcoming investor conferences at the Waldorf Astoria in New York City.

  • 14th Annual BIO CEO & Investor Conference
    • Presentation: 1:30 p.m. EST on Monday, February 13, 2012
  • Leerink Swann 2012 Global Healthcare Conference
    • Presentation: 8 a.m. EST on Thursday, February 16, 2012

About Quizartinib
Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipe
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)...  The Large Urology Group Practice Association ... discredited recommendations by the U.S. Preventive Services Task ... USPSTF,s final recommendation, released today, instructs physicians ... test. This comes despite overwhelming opposition from urologists, ... who have confirmed the importance of these life-saving ...
(Date:5/21/2012)... Genesis Biopharma, Inc. (OTC/BB: GNBP), a ... posting of the following Letter to Shareholders to ... www.genesis-biopharma.com .  In addition, on May 15, ... and Exchange Commission its Quarterly Report for the ... 10-Q.  The Form 10-Q includes unaudited interim consolidated ...
(Date:5/18/2012)... NEW YORK, May 18, 2012  Intellect Neurosciences, ... Chain, the company,s chairman and CEO, will be ... Partnering Conference. (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ... presentation is "Prefibrillar Tau Neoepitopes Offer Attractive Targets ... take place on May 21st at the Intercontinental ...
(Date:5/17/2012)... an effort to voice concern on biosimilars pathways for ... Foundation (IDF) offered oral testimony at last week,s ... on draft guidance of biosimilars products. IDF urged the ... pathways in order to protect the safety of patients ... born with an immune system that is either absent ...
Breaking Biology Technology:Urologists Outraged over Government Panel's Recommendation to Stop Life-Saving Prostate Cancer Testing 2Urologists Outraged over Government Panel's Recommendation to Stop Life-Saving Prostate Cancer Testing 3Genesis Biopharma Issues Letter To Shareholders 2Genesis Biopharma Issues Letter To Shareholders 3Genesis Biopharma Issues Letter To Shareholders 4Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway 2
... as I sat at lunch sending off a series of ... how our professional lives continue to evolve dramatically, and in ... of a company that is driving the adoption of Internet ... quickly technological change continues to transform and enhance our professional ...
... Worst Phone UI Ever, in which I vented my ... Since that column, most people running start ups to develop mobile ... come to tell be about their products. Remarkably, most of these ... well-resourced Cingular and its OEM partner, HTC . ...
... - Norlight Telecommunications, Inc., which will spin ... it will roll out its new Voice over Internet ... Green Bay and Madison. , ,The facilities-based communications ... by offering integrated communications bundles of local voice, long ...
Other Biology Technology:Visions: Rimas Buinevicius, CEO of Sonic Foundry 2Visions: Rimas Buinevicius, CEO of Sonic Foundry 3More women needed in interface design 2More women needed in interface design 3More women needed in interface design 4Norlight will offer VoIP in Madison, Green Bay 2
(Date:5/21/2012)... by financial strategists to determine what shares to purchase ... develop a diversified portfolio of another kind -- land ... uncertainty about climate change. , Instead of plugging into ... stock, University of Illinois environmental economist Amy Ando and ... of the Prairie Pothole Region of the northern Great ...
(Date:5/21/2012)... . ,, Castor oil is known primarily as ... times with pregnant women to induce labour. Only now have ... Research succeeded in unravelling the mysteries of the action mechanism. ... of the intestine and uterus is apparently responsible. This is ... obtained from the seeds of the castor oil plant ...
(Date:5/21/2012)... Ind. - Researchers at Purdue University are working with ... Reed National Military Medical Center to create a new ... brain aneurisms including those caused by head trauma from ... might be inserted at the site of an aneurism ... vessel," said Jean Paul Allain, an associate professor of ...
Breaking Biology News(10 mins):Financial tool considered climate change uncertainty to select land for conservation 2Financial tool considered climate change uncertainty to select land for conservation 3G protein-coupled receptor mediates the action of castor oil 2G protein-coupled receptor mediates the action of castor oil 3Purdue professor to speak before Congress about nanotechnology in brain treatment research 2Purdue professor to speak before Congress about nanotechnology in brain treatment research 3Van Andel research institute study provides new details of fundamental cellular process 23429 1Internal Fixation Systems Announces 510 28k 29 Approval Granted by FDA for Subtalar Implants 23671 1Internal Fixation Systems Announces 510 28k 29 Approval Granted by FDA for Subtalar Implants 23671 2Parents May Hold Key to Treating Kids Obesity 88758 1Parents May Hold Key to Treating Kids Obesity 88758 2
... Fund (WWF) is alarmed by the dramatic decline of at ... Wildlife Reserve in Nepal, once a refuge that boasted among ... Himalayas. The recent survey of April 2008 showed a population ... , The Government of Nepal made a low-key announcement ...
... to produce a lot of a substance -- such as ... molecules that speed chemical reactions. Many jobs require highly specialized ... connect with certain molecules can be difficult. Natural catalysts, such ... food, get around this problem by shape-shifting to suit the ...
... With the goal of developing an accurate, powerful ... bone strength, scientists of the ETH Zurich Departments ... teamed up with supercomputing experts at IBM,s Zurich ... the team combines density measurements with a large-scale ...
Other Biology News:Tigers disappear from Himalayan refuge 2Synthetic molecules emulate enzyme behavior for the first time 2Synthetic molecules emulate enzyme behavior for the first time 3ETH Zurich and IBM improve diagnosis of osteoporosis 2
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Biotin anti-human CD164...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
Biology Products: